News

BASF broadens enzyme business
Enlarge image

BusinessDenmarkGermany

BASF broadens enzyme business

16.05.2013 - German BASF AG has licensed Dyadic International's fungal enzyme manufacturing platform.

The German chemistry major will pay US$6m upfront to access Dyadic's C1 platform technology via a non-exclusive worldwide research and licence agreement. Under the term of the contract, BASF will fund research and development at Dyadic's research lab in the Netherlands and will use its thermophilic fungus Myceliopthora thermophila to develop, produce, distribute and sell industrial enzymes for a variety of applications. The US-headquartered company will cash in certain research and commercial milestone fees, as well as royalties upon commercialisation.  

"Dyadic's C1 technology will strengthen BASF's position in the industrial enzyme industry," said Dr. Carsten Sieden, Senior Vice President Fine Chemicals and Biocatalysis Research, BASF. "We expect this license agreement with Dyadic to result in promising long-term opportunities."

Dyadic's technology platform can be used for development and large scale manufacture of low cost proteins and enzymes as well as for screening of novel genes and proteins.  On the same day, BASF announced it has broadened its existing collaboration with Cologne-based Direvo Industrial Biotechnology GmbH, an expert in enzyme development and optimisation. The companies announced they will jointly develop a highly efficient protease for pig and poultry nutrition. Financial details were not disclosed.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/basf-broadens-enzyme-production.html

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 One of the biggest pharma mergers of the year has been called off. Abbvie has dropped plans to acquire UK’s Shire following new US tax rules.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

PoliticsEULithuaniaPoland

02.10.2014 New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN6.46 EUR16.82%
  • CYTOS0.17 CHF13.33%
  • WILEX2.25 EUR7.14%

FLOP

  • 4SC0.87 EUR-1.14%
  • CYTOTOOLS31.45 EUR-0.47%
  • ADDEX3.20 CHF0.00%

TOP

  • BIOFRONTERA2.88 EUR30.9%
  • ADDEX3.20 CHF3.2%
  • HBM84.00 CHF0.6%

FLOP

  • CYTOS0.17 CHF-29.2%
  • PAION2.22 EUR-27.2%
  • 4SC0.87 EUR-25.6%

TOP

  • SANTHERA82.40 CHF2139.1%
  • CO.DON2.58 EUR163.3%
  • PAION2.22 EUR141.3%

FLOP

  • CYTOS0.17 CHF-95.7%
  • 4SC0.87 EUR-50.6%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 19.10.2014